Alexion Pharmaceuticals (NASDAQ:ALXN) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a note issued to investors on Thursday. The brokerage currently has a $127.00 price target on the biopharmaceutical company’s stock. Zacks Investment Research‘s price objective indicates a potential upside of 17.83% from the stock’s previous close.
According to Zacks, “Alexion’s blockbuster drug, Soliris, continues to perform well and the FDA approval of the drug for generalized myasthenia gravis is likely to boost sales further. The prospects of ALXN1210 looks good too and a tentative approval will boost the top-line. Alexion is looking to diversify its portfolio and reduce its dependence on its blockbuster drug Soliris. The recently announced Wilson deal will strengthen Alexion’s rare disease pipeline with a late-stage candidate, WTX101 which is currently in phase III for the treatment of Wilson disease, a rare genetic disorder. Earlier, Alexion has de-prioritized a few clinical programs and terminated partnerships with Moderna Therapeutics among others. Shares of the company have performed better than the industry in the last three months. However, the company relies heavily on Soliris for growth and sales of the same will be impacted by ramp-up of ALXN1210 trials. Pricing will also hit sales.”
A number of other equities research analysts have also recently commented on the stock. Nomura increased their target price on shares of Alexion Pharmaceuticals to $165.00 and gave the company a “buy” rating in a research report on Thursday, April 12th. BidaskClub upgraded shares of Alexion Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Wednesday, December 27th. UBS cut shares of Alexion Pharmaceuticals from a “strong-buy” rating to an “outperform” rating in a research report on Thursday, January 4th. Credit Suisse Group reiterated an “outperform” rating and issued a $147.00 target price on shares of Alexion Pharmaceuticals in a research report on Thursday, January 18th. Finally, SunTrust Banks set a $172.00 price objective on shares of Alexion Pharmaceuticals and gave the stock a “buy” rating in a research report on Monday, February 12th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and twenty-one have assigned a buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $155.18.
Shares of NASDAQ ALXN opened at $107.78 on Thursday. The stock has a market capitalization of $24,846.32, a PE ratio of 22.04, a price-to-earnings-growth ratio of 1.00 and a beta of 1.13. The company has a quick ratio of 2.62, a current ratio of 3.10 and a debt-to-equity ratio of 0.34. Alexion Pharmaceuticals has a 52 week low of $96.18 and a 52 week high of $149.34.
Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its earnings results on Thursday, February 8th. The biopharmaceutical company reported $1.48 EPS for the quarter, beating the Zacks’ consensus estimate of $1.09 by $0.39. The business had revenue of $909.70 million during the quarter, compared to analysts’ expectations of $880.38 million. Alexion Pharmaceuticals had a net margin of 12.48% and a return on equity of 12.94%. The company’s quarterly revenue was up 9.5% compared to the same quarter last year. During the same period in the prior year, the business earned $1.26 earnings per share. equities research analysts predict that Alexion Pharmaceuticals will post 6.12 EPS for the current fiscal year.
In other Alexion Pharmaceuticals news, CEO Ludwig Hantson sold 13,245 shares of the stock in a transaction dated Thursday, February 8th. The shares were sold at an average price of $116.31, for a total transaction of $1,540,525.95. Following the completion of the transaction, the chief executive officer now owns 131,425 shares of the company’s stock, valued at $15,286,041.75. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP John B. Moriarty sold 3,363 shares of the stock in a transaction dated Thursday, February 8th. The stock was sold at an average price of $115.70, for a total transaction of $389,099.10. Following the transaction, the executive vice president now directly owns 71,400 shares of the company’s stock, valued at approximately $8,260,980. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 28,700 shares of company stock valued at $3,345,708. 4.35% of the stock is currently owned by insiders.
Hedge funds have recently made changes to their positions in the business. Delpha Capital Management LLC purchased a new position in Alexion Pharmaceuticals during the fourth quarter worth about $102,000. CNB Bank purchased a new position in Alexion Pharmaceuticals during the fourth quarter worth about $150,000. Lourd Capital LLC purchased a new position in Alexion Pharmaceuticals during the fourth quarter worth about $221,000. CIBC World Markets Inc. purchased a new position in Alexion Pharmaceuticals during the fourth quarter worth about $263,000. Finally, Bailard Inc. purchased a new position in Alexion Pharmaceuticals during the fourth quarter worth about $263,000. 95.09% of the stock is owned by institutional investors.
ILLEGAL ACTIVITY NOTICE: “Alexion Pharmaceuticals (ALXN) Rating Increased to Buy at Zacks Investment Research” was published by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are viewing this report on another site, it was stolen and reposted in violation of US and international trademark and copyright legislation. The legal version of this report can be viewed at https://www.thelincolnianonline.com/2018/04/21/alexion-pharmaceuticals-alxn-rating-increased-to-buy-at-zacks-investment-research.html.
Alexion Pharmaceuticals Company Profile
Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers Soliris (eculizumab), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; atypical hemolytic uremic syndrome (aHUS), a genetic disease; and generalized myasthenia gravis, a debilitating, complement-mediated neuromuscular disease.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.